COVID-19

Excerpt from the Article: When the COVID-19 pandemic hit, researchers in Canada and around the world moved quickly to pivot their research and help with the development of new treatments and vaccines.  At The Ottawa Hospital, this resulted in more than 60 different research projects and trials, including an innovative clinical trial of mesenchymal stem…

Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) — Vaxart, Inc., (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral vaccines administered by tablet, today announced preliminary data from its Phase 1 study of VXA-CoV2-1 showing that its oral COVID-19 tablet vaccine candidate was generally well-tolerated, and immunogenic as measured by…

Excerpt from the Press Release: RADNOR, Pa. and IRVINE, Calif., Feb. 3, 2021 /PRNewswire/ — NeuroRx, Inc. today announced initiation of a Phase 2/3 clinical trial investigating the role of inhaled ZYESAMI™ (aviptadil) for the treatment of patients with Severe COVID-19 in partnership with UCI Health of the University of California, Irvine. UCI Health was…

Excerpt from the Press Release: BOSTON, Feb. 04, 2021 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that the first patient has been dosed in the Phase 2 virology trial evaluating AT-527 in mild or moderate COVID-19 patients in an outpatient setting. The trial will enroll patients in…

Excerpt from the Press Release: BURLINGAME, Calif., Feb. 04, 2021 (GLOBE NEWSWIRE) — Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it has initiated a Phase 3 clinical trial of CPI-006 for the treatment of hospitalized patients with COVID-19. The study is expected to enroll approximately 1,000 patients at sites in…

Excerpt from the Press Release: BURLINGAME, Calif.–(BUSINESS WIRE)–Humanigen, Inc. (NASDAQ:HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate lenzilumab™, today announced it has completed enrollment for its pivotal phase 3 study of lenzilumab for COVID-19. The Company expects to announce top-line…

Excerpt from the Press Release: “The ability to run a single, highly-sensitive test that detects SARS-CoV-2, Flu A, Flu B, and respiratory syncytial virus provides actionable results and helps to alleviate pressure on the healthcare system,” said Dr. David Persing, MD, Ph.D., Chief Medical and Technology Officer at Cepheid. “Xpert® Xpress SARS-CoV-2/Flu/RSV delivers reference lab quality testing in…

Excerpt from the Article: Images captured with fMRI in a case study reveal the role of the orbitofrontal cortex in patients infected with the virus who experience anosmia and ageusia. Functional MRI (fMRI) has helped increase understanding about the loss of smell and taste that frequently accompany COVID-19 infection. The answer lies in the orbitofrontal…

Excerpt from the Article: A made-in-Canada vaccine to protect against COVID-19 began human clinical trials Tuesday in Toronto, says the biotechnology company that developed the vaccine. Toronto-based Providence Therapeutics said three shots will be given to 60 adult volunteers at a clinical trial site in Toronto in the first phase of the trial on Tuesday.  Fifteen of…

Excerpt from the Article: LA JOLLA, CA—A big question on people’s minds these days: how long does immunity to SARS-CoV-2 last following infection? Now a research team from La Jolla Institute for Immunology (LJI), The University of Liverpool and the University of Southampton has uncovered an interesting clue. Their new study suggests that people with…